Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution
-
Marta Sotelo [1] ; Nerea Muñoz Unceta [1] ; Antonio Matorras [2] ; Pablo Jara [1] ; Clara Castro [1] ; Diego Cacho [1] ; Belén Caramelo [1] ; Ainara Azueta [1] ; Ignacio Durán [1]
-
[1] Hospital Universitario Marqués de Valdecilla
Hospital Universitario Marqués de Valdecilla
Santander, España
-
[2] Universidad de Cantabria
Universidad de Cantabria
Santander, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 3, 2024, págs. 682-688
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment of metastatic urothelial carcinoma (mUC) upon platinum-based chemotherapy according to the positive results of large clinical trials. Nevertheless, results from unselected populations reflecting real-world data (RWD) are highly informative to the clinician. We reviewed daily clinical practice outcomes in patients with mUC who received atezolizumab in our institution.
Methods Here we evaluated the clinical activity and safety of atezolizumab in an unselected population of mUC patients who received atezolizumab between 2018 and 2022 reflecting RWD. Efficacy and safety information were retrospectively collected.
Results A total of 63 patients were included. The mean age was 68 years and the objective response rate was 14.3%. The median progression-free survival was 3 months and the median overall survival 6 months. At 1 year, 42% of the patients were alive. ECOG (0 vs 1) and neutrophil–lymphocytes ratio < 2 at the start of ICI were positive prognostic factors that discriminated between long vs short survivors. Overall tolerance was good with no new safety signals. Five patients (17%) had treatment-related adverse events grade ≥ 2 that required corticosteroids.
Conclusion In this retrospective study, atezolizumab was an effective and tolerable treatment option for patients with mUC after progression to platinum-based chemotherapy. Yet, patient selection remains critical to improve outcomes.
